Validation demand is lumpy. Three systems land in the same quarter, then nothing for months. Hiring for the peak is expensive and hiring for the trough leaves you stuck, so almost every regulated company outsources some of it.
The question is which parts. Some work transfers cleanly to a partner; some never should, and the difference is not about difficulty.
What transfers well
- Execution capacity. Running scripted protocols, capturing evidence, assembling packages — volume work with a defined output.
- Specialist depth you need rarely. SAP, MES or SCADA validation once every few years is not worth building in-house. See SAP and MES validation.
- Methodology change. Bringing in people who have made the CSA transition several times is usually faster and cheaper than learning it from guidance.
- Backlog clearance. Overdue periodic reviews, validation debt on legacy systems — bounded work with a clear finish.
- Steady-state operations once a model is established, through managed services.
What should stay with you
The risk decisions. What could go wrong and how much it matters depends on knowing your process, your product and your patients. A partner can facilitate the assessment; they cannot own the judgement.
QA approval. Your quality unit approves, full stop. A supplier approving their own work is not independent review, whatever the contract says.
Requirements. The process owner owns what the system must do. Outsourced requirements produce documents that describe software rather than work — see roles and responsibilities.
System ownership. A named person inside your organisation owns each system through its life, including after the project ends.
And the point behind all of these: the regulator holds you accountable. You can contract out the work; you cannot contract out the responsibility. When an inspector asks why a decision was made, the answer cannot be that the consultant decided.
Running it so it works
- Qualify them like any supplier. Their quality system, their people's training, how they handle deviations. See supplier qualification.
- Write down who does what, deliverable by deliverable, including who approves. Ambiguity here is where packages stall.
- Insist on your templates and your terminology, or you will inherit a package that does not match your SOPs and has to be reworked.
- Review early output in detail. The first deliverable sets the standard for everything after it.
- Plan the handover from day one. Who maintains validated status when the engagement ends? Knowledge that leaves with the partner is the most common hidden cost.
- Avoid full dependency. Keep enough capability in-house to judge the work. A team that cannot evaluate its supplier has outsourced its judgement too.
For where tooling reduces the capacity problem in the first place, see GxP software and validation metrics that matter.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.